Lineage Cell Therapeutics’ (LCTX) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) in a research note issued to investors on Monday morning,Benzinga reports. They currently have a $2.00 price objective on the stock.

Separately, HC Wainwright reissued a “buy” rating and set a $9.00 target price on shares of Lineage Cell Therapeutics in a research note on Monday, November 24th. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $4.67.

Lineage Cell Therapeutics Stock Performance

Shares of NYSEAMERICAN LCTX opened at $1.80 on Monday. Lineage Cell Therapeutics has a fifty-two week low of $0.37 and a fifty-two week high of $2.09. The company has a market cap of $414.59 million, a price-to-earnings ratio of -6.21 and a beta of 1.80. The business’s 50 day moving average price is $1.69 and its 200-day moving average price is $1.56.

Institutional Investors Weigh In On Lineage Cell Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Royal Bank of Canada grew its holdings in Lineage Cell Therapeutics by 1,578.9% in the first quarter. Royal Bank of Canada now owns 528,656 shares of the company’s stock worth $237,000 after purchasing an additional 497,168 shares during the last quarter. Rhumbline Advisers boosted its position in shares of Lineage Cell Therapeutics by 9.9% in the 1st quarter. Rhumbline Advisers now owns 201,447 shares of the company’s stock worth $91,000 after purchasing an additional 18,092 shares in the last quarter. Defender Capital LLC. grew its stake in Lineage Cell Therapeutics by 7.5% during the 2nd quarter. Defender Capital LLC. now owns 6,785,177 shares of the company’s stock worth $6,157,000 after buying an additional 474,304 shares during the last quarter. Cannon Global Investment Management LLC purchased a new position in Lineage Cell Therapeutics during the 2nd quarter worth $30,000. Finally, Ground Swell Capital LLC acquired a new position in Lineage Cell Therapeutics during the 2nd quarter valued at about $95,000. Hedge funds and other institutional investors own 62.47% of the company’s stock.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.

Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.